Timothy E. Morey
Corporate Officer/Principal bei University of Florida
Profil
Dr. Timothy E.
Morey, MD, is a Professor at University of Florida and a Principal at Kegonsa Capital Partners LLC.
He is on the Board of Directors at Nanomedex Pharmaceuticals, Inc.
He received his doctorate degree from the University of Florida.
Aktive Positionen von Timothy E. Morey
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Florida | Corporate Officer/Principal | 25.11.2009 |
Ehemalige bekannte Positionen von Timothy E. Morey
| Unternehmen | Position | Ende |
|---|---|---|
NanoMedex Pharmaceuticals, Inc.
 NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Gründer | - |
Ausbildung von Timothy E. Morey
| University of Florida | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
NanoMedex Pharmaceuticals, Inc.
NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Health Technology |
